QNCX - NASDAQ
Quince Therapeutics, Inc.
$1.36
+0.0000%Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotQuince Therapeutics, Inc. Management Team
Mr. Brendan Hannah M.B.A.
Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer
Compensation
$579,875
Dr. Dirk Thye M.D.
Chief Executive Officer, Chief Medical Officer & Director
Compensation
$767,125
Dr. Guenter R. Janhofer M.D., Ph.D.
Chief Scientific Officer
Mr. Giovanni Mambrini M.Sc.
Chief Technology Officer
Dr. Stewart A. Low Ph.D.
Head of Discovery
Ms. Pamela M. Williamson FRAPS, M.B.A., RAC
Head of Regulatory Affairs
Dr. Charles S. Ryan J.D., Ph.D.
President
Compensation
$703,100
Ms. Stacy Roughan
Vice President of Corporate Communications & Investor Relations
Ms. Mary Ellen Sillivos
Vice President of Human Resources
Quince Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $441K and sold $174K worth of QNCX shares, resulting in $268K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
50.0K
173.50K
-174K
-$174K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
385.2K
441.48K
0
0.00
+441K
+$441K
Top Buyers
Thye Dirk
Director, Officer: Ceo And Cmo
$181K
Hannah Brendan
Officer: Cbo, Coo & Cco
$45K
Benatti Luca
Director
$29K
Senner Christopher J.
Director
$29K
Lamond David
Director
$29K
Top Sellers
Benatti Luca
Director
$174K
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $268K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
QNCX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 14, 2023 | April 14, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 22, 2020 | June 08, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.